News Release

Innovate Biopharmaceuticals to Highlight Progress in Celiac Disease and NASH at the Cowen Healthcare Conference on March 13, 2018, Tuesday at 8:40 AM ET

Mar 07, 2018

RALEIGH, N.C., March 07, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq:INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, announced company executives are scheduled to present at the Cowen Healthcare Conference on Tuesday, March 13, 2018, at 8:40 am ET in the Orleans presentation room on the 4th floor at the Boston Marriott Copley Place located at 110 Huntington Avenue in Boston. 

The presentation will be followed by a breakout session from 9:20 am to 9:50 am ET in the Hyannis Room on the 4th floor.

About Innovate Biopharmaceuticals, Inc.(Nasdaq:INNT):
Innovate is a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases. Innovate’s lead drug candidate, larazotide acetate, has a mechanism of action which decreases intestinal permeability and regulates tight junctions across the intestinal epithelial barrier by reducing antigen trafficking, such as gliadin fragments in celiac disease, and lipopolysaccharide (LPS) in nonalcoholic steatohepatitis (NASH). In several diseases, including celiac disease, NASH, inflammatory bowel diseases (IBD, Crohn’s disease and ulcerative colitis), irritable bowel syndrome (IBS), type 1 diabetes mellitus (T1DM), chronic kidney disease (CKD), intestinal permeability is increased. To the company’s knowledge, larazotide is the only drug candidate in clinical testing which reduces intestinal permeability, also referred to as “leaky gut.”

In celiac disease, larazotide is the only drug which has successfully met the primary endpoint in a Phase 2b efficacy clinical trial with statistical significance (342-patients enrolled). Innovate successfully completed the End of Phase 2 Meeting with the FDA in 2017 and is preparing for larazotide to begin Phase 3 registration clinical trials for celiac disease around mid-2018. In clinical trials testing of more than 500 patients exposed to it, larazotide demonstrated a favorable safety profile comparable to placebo for long-term chronic administration. Larazotide has received Fast Track designation from the FDA for celiac disease.

Forward Looking Statements

This press release includes forward-looking statements including, but not limited to, statements related to the potential for Innovate’s drug development pipeline candidates in treating the diseases and conditions for which they are being developed, Innovate’s start of clinical trials for celiac disease, NASH, Crohn’s disease and ulcerative colitis, and Innovate’s ability to develop future collaborations. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, the success, timing and cost of ongoing or future clinical trials, the lengthy and unpredictable nature of the drug approval process, and our ability to commercialize our product candidates if approved. These risks and uncertainties include, but may not be limited to, those described in our Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 2, 2018, and in any subsequent filings with the SEC.  Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

Innovate Biopharmaceuticals, Inc.
Kendyle Woodard
Tel: 919-275-1933
Email: investor.relations@innovatebiopharma.com
www.innovatebiopharma.com

Primary Logo

Source: Innovate Biopharmaceuticals, Inc

Copyright West LLC. Minimum 15 minutes delayed.